Avalo Therapeutics, Inc. (AVTX)
14.43
+0.01
(+0.07%)
USD |
NASDAQ |
Apr 17, 16:00
14.59
+0.16
(+1.11%)
After-Hours: 06:57
Avalo Therapeutics SG&A Expense (Quarterly) : 6.534M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Catalyst Pharmaceuticals, Inc. | 48.23M |
| AbbVie, Inc. | 3.895B |
| Relmada Therapeutics, Inc. | 12.26M |
| Theravance Biopharma, Inc. | 20.96M |
| Corcept Therapeutics, Inc. | 130.24M |